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costs and Life-years gained (LYG) offset based on incremental survival rate of compared 
therapies. Probabilistic Multivariable sensibility analysis was completed with 5,000 
simulated patients. Results: Survival rate and confidence interval obtained from 
model was 0.63 (0.60, 0.66) for paricalcitol and 0.46 (0.44, 0.48) for PTX. Average survival 
of both therapies resulted in an incremental 0.61 LYG for paricalcitol patients (+18%). 
Average five years treatment cost for Paricalcitol patients was $10,024.25, while PTX 
was US$5,369.74(-46%) resulting in an ICER of US$7,619.94 per LYG, which is 28.2% 
below Mexican Gross Domestic Product (GDP) per capita. Probabilistic analysis shown: 
90.1% of patient treated had a cost-effective outcome and 7.2% of cases had a domi-
nant outcome. ConClusions: According to results obtained and using a threshold 
of US$29,306.29 (3 x GDP per capita), Paricalcitol is a highly cost-effective treatment 
option compared to PTX when treating patients with SHPT at IMSS.
PDB10
Cost-EffECtivEnEss of fixED-DosE ComBination (fDC) of vilDagliPtin/
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objeCtives: Type 2 Diabetes is a major public health care problem in Mexico. Some 
patients may require more than one oral antidiabetic treatment to achieve glycemic 
control. Vildagliptin, a DPPIV inhibitor is an option in combination with the stand-
ard treatment of metformin. The objective was to assess the cost-effectiveness of 
Vildagliptin/Metformin FDC versus other oral treatments available in the public 
market. Methods: Cost-effectiveness analysis of the oral antidiabetic treatments 
available in the public market in Mexico was conducted. The comparisons included 
the following options: Vildagliptin/Metformin FDC, glibenclamide, and thiazolidin-
ediones (Rosiglitazone and pioglitazone). Cost effectiveness analysis versus other 
oral antidiabetics incorporated the incidence and costs of adverse events according 
to Ferrannini 2009 and Gonzalez-Ortíz 2009 for glibenclamide and Motola 2012 for 
thiazolidinediones. Drug costs were elicited from public tenders and health care 
services from unitary costs of the IMSS. The perspective is the public health provider 
and the time horizon is one year. Results: The use of Vildagliptin/Metformin FDC 
(50/500 or 850 mg) BID compared to glibenclamide, is a dominant strategy if the cost 
per hypoglycemia exceeds US$714.03. Vildagliptin/Metformin FDC is dominant ver-
sus pioglitazone,if the cost of fractures incurred by pioglitazone exceeds US$56.56. 
Drug acquisition costs of Vildagliptin/Metformin FDC are 150% cheaper per patient 
treated vs rosiglitazone; additionally rosiglitazone is associated with myocardial 
infarction events. ConClusions: Vildagliptin/Metformin FDC is an opportunity 
for resource optimization in the public sector. This cost effectiveness analysis is 
not considering other potential adherence benefits which are related with having 
two treatments in one pill.
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objeCtives: To perform a probabilistic sensitivity analysis to analyze previously 
reported results about the cost-effectiveness of oral hypoglycemic agents (OHA’s) 
in the initial oral drug treatment of patients diagnosed with type 2 diabetes mel-
litus in public primary attention in Mexico. Methods: A probabilistic sensitivity 
analysis was made in order to analyze results previously reported in which a deter-
ministic sensitivity analysis was performed to study the cost-effectiveness of three 
OHA’s: metformin, glibenclamide and acarbose. We used TreeAge-Pro® software for 
programming and simulating a Markov model of two health states (HbA1C≤ 7% or 
HbA1C> 7%) and twelve cycles of 1 month for a time horizon of 1 year. The parameters 
of monthly success probability as beta distributions and monthly costs as lognormal 
distributions of therapeutic alternatives were computed through a parametrization 
of data. Monte Carlo’s simulations were computed for cohorts of 10,000 patients 
for each treatment option. Results: The results of the Monte Carlo’s simulations 
showed very close iterations clouds for metformin and glibenclamide showing evi-
dent dominance of both over acarbose. In the acceptability curve generated, for a 
willingness to pay (WTP) = 0 the probabilities to be cost-effective were 49.46 %, 43.04 
% and 7.50 % for glibenclamide, metformine and acarbose, respectively, whereas for 
a WTP = 1 mexican GDP per capita (US $ 7876.00 in 2009) were 66.26 %, 26.98 % and 
6.76%. The glibenclamide versus metformin incremental cost-effectiveness analysis 
showed similar results as mentioned before, showing 59.72% of iterations below the 
WTP = 1 mexican GDP per capita line. ConClusions: The probabilistic sensitivity 
analysis showed which the initial drug therapy with glibenclamide or metformin 
have advantage over acarbose. There is not sufficient evidence to say glibenclamide 
has advantage over metformin for WTP near to cero, as in low to middle income 
countries where containment of expenditures is important.
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objeCtives: Canagliflozin (CANA) is a novel inhibitor of the sodium glucose co-
transporter 2 in development for treating patients with type 2 diabetes mellitus 
(T2DM). In a previously reported randomized, double-blind, 4 arm parallel group 
(placebo, CANA 100mg, CANA 300mg and sitagliptin 100mg [SITA]) study of 1284 
subjects inadequately controlled on MET monotherapy, CANA 100mg and 300mg 
significantly decreased HbA1c versus placebo after 26 weeks of therapy by 0.62% and 
0.77%, respectively; SITA decreased HbA1cversus placebo by 0.65%. In this trial, both 
9% of total cost of T2DM. The cost estimate was most sensitive to incidence and event 
cost of peripheral vascular disease, stroke and severe vision loss. ConClusions: 
Based on the present analysis, T2DM places a significant financial burden on the 
health care system in Mexico, with cost of treating related complications being the 
main cost driver. Given the model focuses on diagnosed and treated T2DM patients, 
it is likely this cost is even higher when undiagnosed and untreated patients are 
considered. Delaying the onset of complications could result in a reduction in costs, 
as well as benefits for the patient and health care system.
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objeCtives: This study aimed to quantify the annual financial cost of type 2 diabe-
tes (T2DM) in Brazil and explore the relative contribution of different components 
of cost. Methods: A cost of illness model was developed in Microsoft Excel 2007 
to estimate the financial cost of T2DM in Brazil from the public health care payer 
perspective. Cost of routine management and complications were included in the 
analysis. Data inputs for prevalence of T2DM (weighted to include only patients who 
are diagnosed and treated) and related complications, costs and routine management 
were sourced from the published literature and publicly available databases, where 
available. Key opinion leader input was sought to fill data gaps. Sensitivity analyses 
were conducted to identify parameters which were most likely to impact overall 
results when varied. Costs are presented in Brazilian Reals 2012. Results: The annual 
cost of T2DM in Brazil is estimated to be 11,275,921,167 BRL ($5,471,123,022USD) which 
represents 5.3% of national health care expenditure. Costs of complications were 
estimated to account for 56% of the total cost of T2DM. Cardiovascular complica-
tions accounted for 32% of total T2DM cost. Diabetes drug costs were estimated to 
account for 31% of total T2DM health care spending. The overall cost estimate was 
most sensitive to the laser eye surgery, hemodialysis and cardiovascular complica-
tions and the frequency and cost of routine physician consultations. ConClusions: 
The findings indicate that there is a high economic burden of T2DM for the Brazilian 
health care system. Cost of treating related complications was the main driver. An 
even higher burden of the disease is expected if undiagnosed and patients currently 
not being treated start receiving public medical attention. The burden of the disease 
could considerably be reduced if T2DM related complications were avoided, which 
not only benefits the health care system but the patients as well.
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objeCtives: Diabetes is one of the most common chronic diseases in Canada. It 
affects about 6.8% of the Canadian population. Treating and managing the disease 
and its complications is associated with a significant economic burden. The objec-
tive of this study was to analyse trends in terms resource utilization, cost and treat-
ment patterns in the management of diabetes. Methods: Patients covered by the 
Quebec provincial drug reimbursement program (RAMQ) who had a diagnosis of 
diabetes, in 2005 and were covered continuously by the public drug program for the 
period from January 2006 to December 2010 were selected. Health care resources in 
terms of diabetes medications and physician visits, hospitalization, intensive care 
unit stay, hospital outpatient clinic visits, and emergency room visits associated 
with a diagnosis of diabetes were estimated over a 5-year period, from January 2006 
to December 2010. Trends in the proportion of diabetes medications used each year 
over the 5-year study period were also estimated. Results: A total of 46,194 diabetic 
patients were included in the study. The mean age of the study population was 65.4 
years (SD= 12.3) and proportion of male/female was 47% and 53% respectively. Over 
the study period, annual cost of diabetes medications varied from $320 (SD= 464) in 
2006 to $372 (SD= 546) in 2010 (+16%) while total cost of treatment associated with 
diabetes varied from $627 (SD= 1456) to $715 (SD= 1632) (+14%) during that period. 
Metformine remains the most widely used medication throughout the study period 
with 64.3% of users in 2006 and 65.6% in 2010. Proportion of insulin users increased 
from 15.2% to 22.7% while gliclazide users increased from 4.4% to 11.2% during the 
study period. ConClusions: Over the five-year study period cost of diabetes treat-
ment has increased at a rate similar to inflation, while trends of increased adoption 
of insulin and newer medications is observed.
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Cost-EffECtivEnEss of PariCalCitol vErsus ParathyroiDECtomy 
for sEConDary hyPErParathyroiDism to ChroniC KiDnEy DisEasE in 
mExiCo
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objeCtives: Secondary hyperparathyroidism (SHPT) affects one of every two 
Mexicans with chronic kidney disease (CKD) at stage five. The objective of this research 
was to assess cost effectiveness (CE) of Paricalcitol intravenous administration (IV) ver-
sus parathyroidectomy (PTX) from Mexican payer perspective. Methods: A decision 
tree model was designed to simulate patient resources usage and survival rate in 5 
years time-frame treated with paricalcitol IV and parathyroidectomy based on clinical 
data in recent published literature. Time-frame begins when a patient is refractory 
to Calcitriol therapy and physician decides to treat with Paricalcitol or program PTX. 
Resources usage considered were just directly related to SHPT treatment: drug cost, 
surgery and hospitalization costs and medical supplies linked. Unit costs were col-
lected from Mexican Government Databases: IMSS official database, Diagnosis Related 
Groups from IMSS, Official Journal of the Federation. (Cost considered 5% annual dis-
count rate).Incremental Cost-Effectiveness Ratio (ICER) was calculated with treatment 
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objeCtives: To assess the cost-effectiveness (CE) of switching from NPH insulin 
± oral glucose-lowering drugs (OGLDs) to insulin detemir ± OGLDs in people with 
type 2 diabetes (T2DM) in countries in different economic circumstances based on 
observational data gathered in routine clinical practice. Methods: The A1chieve
® 
study assessed safety and outcomes over 24 weeks in 66,726 people with T2DM 
starting insulin analog therapy. Most people (96%) stated better glycemic control 
as reason to switching therapy, with 31% also stating hypoglycemia problems as 
a further reason. The CE analyses included data for people switching to detemir 
in South Korea (n= 90) and in seven Arabian Gulf countries (n= 124). Data were col-
lected on clinical effectiveness and adverse events, and health-related quality of 
life using the EQ-5D questionnaire. CE analyses used the IMS CORE diabetes model 
with 1 and 30 year time horizons, with South Korea and Saudi Arabia country-
specific costs for complications and therapies and background mortality rates. CE 
was measured by comparing outcomes at study-end with outcomes at pre-study. 
Incremental cost-effectiveness ratios (ICERs) are expressed as cost per QALY in 
local currencies, USD and in fractions of local GDP per capita. CE was pre-defined 
using the WHO definition of < 3 times GDP per capita. Results: 1-year ICERs were: 
South Korea (KWR 3,236,798; USD 2,980; GDP 0.13), and Saudi Arabia (SAR 27,221; 
USD 7,258; GDP 0.36). 30-year ICERs were: South Korea (KWR 872,589; USD 803; 
GDP 0.04), and Saudi Arabia (SAR 6,349; USD 1,693; GDP 0.08). Sensitivity analyses 
covering cost of self-monitoring, deterioration of glucose control with time, and 
other time horizons showed the results to be robust. ConClusions: Switching 
from NPH±OGLDs to detemir±OGLDs in people with T2DM as performed in the 
A1chieve
® study was found to be cost-effective in both country settings at 1 and 
30 year time horizons.
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objeCtives: To assess the cost-effectiveness (CE) of switching from insulin glargine ± 
oral glucose-lowering drugs (OGLDs) to insulin detemir ± OGLDs in people with type 2 
diabetes (T2DM) in Saudi Arabia, South Korea and Algeria based on observational data 
gathered in routine clinical practice. Methods: The A1chieve
®study assessed safety 
and outcomes over 24 weeks in 66,726 people with T2DM starting insulin analog ther-
apy. The CE analyses included people switching to detemir in Saudi Arabia (n= 102), 
South Korea (n= 82) and in 3 North-West African countries (n= 94). Data were collected 
on clinical effectiveness and adverse events, and health-related quality of life using 
the EQ-5D questionnaire. CE analyses used the IMS CORE diabetes model with 1 and 
30 year time horizons, with Saudi Arabia, South Korea and Algeria country-specific 
costs for complications and therapies and background mortality rates. Incremental 
cost-effectiveness ratios (ICERs) are expressed as cost per QALY in local currencies, 
USD and in fractions of local GDP per capita. CE was pre-defined using the WHO defi-
nition of < 3 times GDP per capita. Results: The switch was found to be less costly 
and have better outcomes in South Korea after 30 years and in Saudi Arabia at both 
time horizons. 1-year ICERs were: Saudi Arabia (SAR -5,849; USD -1,559; GDP -0.08), 
South Korea (KWR 296,842; USD 273; GDP 0.01), and Algeria (DZD 267,771; USD 3,363; 
GDP 0.80). 30-year ICERs were: Saudi Arabia (SAR -14,839; USD -3,957; GDP -0.19), South 
Korea (KWR -1,133,202; USD -1,043; GDP -0.05), and Algeria (DZD 226,818; USD 2,849; 
GDP 0.68). Sensitivity analyses on the 30 year time horizon showed the findings to be 
robust. ConClusions: Switching from glargine±OGLDs to detemir±OGLDs in T2DM 
as performed in the A1chieve
® study was found to be cost-effective across all country 
settings at 1 and 30 year time horizons.
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objeCtivos: Estimar y caracterizar el impacto de la enfermedad sobre la productivi-
dad laboral de personas con diabetes (DM) en Argentina. MetodologíAs: Estudio 
descriptivo observacional relevando información mediante el cuestionario WPAI-GH 
(Work productivity and activity impairment - General Health version) en personas 
adultas (18 a 75 años) con DM, que concurrieron a su consulta habitual a dos centros 
asistenciales de La Plata. Los encuestados también respondieron sobre aspectos 
socioeconómicos y complicaciones de su enfermedad. La pérdida de productividad 
se estimó por el método del capital humano. Los resultados se presentan como 
media ± desvío estándar (DS) o proporciones. Para las comparaciones se utilizaron 
los test t de student, Kruskal-Wallis y Chi cuadrado, según correspondiera. Se con-
sideró significativo p< 0,05. ResultAdos: Aceptaron participar en el estudio 73 
personas con DM; 54,8% hombres con edad de 57 ± 15 años. El 42,5% poseía estudios 
superiores (nivel terciario o universitario completo). El 60,3% trabajaba, 6.4% estaba 
desempleado y el 33,3% inactivo (jubilado, pensionado). El tiempo promedio de tra-
bajo fue de 43 ± 17 horas/semana y el 38% faltó/retiró de su trabajo por su enferme-
dad. El tiempo de trabajo perdido por ausentismo fue 9.1%, y por disminución de 
la productividad el 22%. La diabetes también disminuyó un 25% la capacidad para 
realizar actividades regulares diarias, afectando más a mujeres que a hombres (30 
y 20,3%, respectivamente). La pérdida de productividad monetaria por ausentismo 
CANA doses and SITA significantly reduced systolic blood pressure (CANA 100mg: 
5.36 mmHg; CANA 300mg: 6.58 mmHg; SITA 3.34 mmHg), however, only CANA sig-
nificantly reduced body weight (CANA 100mg: 2.5%; CANA 300mg: 2.9%) versus 
placebo. The objective of this study was to simulate the health outcomes and associ-
ated costs attributable to using CANA versus SITA in Mexico. Methods: Forty-year 
outcomes associated with adding CANA 100mg or CANA 300mg versus SITA to 
MET were simulated using ECHO (Economic and Health Outcomes)-T2DM, a vali-
dated micro-simulation model. Treatment effects and patient characteristics were 
sourced from the trial. Simulated treatment was intensified when HbA1cexceeded 
7.5% by adding basal insulin, and subsequently prandial insulin. Disutilities associ-
ated with micro- and macro-vascular events were obtained from the literature and 
costs were adapted to the Mexican setting. Results: Using CANA 300mg versus 
SITA was projected to reduce relative risks for key events (e.g. myocardial infarction 
10.2%; congestive heart failure 6.6%; macroalbuminuria 6.6%; microalbuminuria 
6.2%), improve QALYs (0.046), and result in lower costs per patient ($1927MXN). 
Simulation results of CANA 100mg versus SITA were generally similar, albeit esti-
mates of reductions in relative risks, QALY gains and associated costs differences 
were smaller. ConClusions: These simulations suggest that using CANA versus 
SITA as an add-on to MET could result in improved outcomes and reduced costs 
in Mexico.
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objeCtives: Compare expected costs and health-outcomes in patients with 
Diabetes Mellitus Type 2 (DMT2) in the Public Sector in Mexico treated with 
glargine or 25%-insulin lispro, 75%-insulin lispro protamine suspension 
(LM25). Methods: This analysis included a hypothetical cohort of insulin-naïve 
patients with T2DM, aged 30–80, years, with A1C> 7.0% taking antihyperglycemic 
drugs for 90 days. Effectiveness measures included; (1) Percentage of patients with 
A1C< 7.0% levels at 24 weeks, (2) frequency and type of micro and macrovascular 
complications (MMVC) and (3) hypoglycemic events per 1000 patients consider-
ing one-year timeframe. Costs evaluated were: 1) acquisition costs; 2) cost of 
hypoglycemic events; and 3) MMVC. Efficacy measures and mean-daily-dose was 
obtained from DURABLE, parallel, open-label and randomized study comparing 
directly LM25 and Glargine. Incidences of MMVC were estimated using data from 
UKPDS study group and data from Meta-analysis by Quayum following a similar 
process outlined by Grima. Acquisition costs were derived from the transparency 
portal of the Mexican Social Security Institute. Healthcare services utilization 
from hypoglycemic episodes were calculated according to international published 
literature and IMSS Unit Costs updated to 2013 following IMSS methodology, while 
other associated expenses with MMVC complications come from Mexican reports 
and Diagnostic Related Groups (DRG) published by IMSS this data was updated to 
January 2013 using the Bank of Mexico inflation calculator. Costs are expressed 
in 2013 USD (1USD= $12.70MXN) Results: All results consider 1000 patients 
treated in a 1-yeat timeframe. Acquisition costs for LM25 were lower compared 
to glargine ($291,395 vs $383,521, 24% lower), although costs per hypoglycemia 
events were higher for LM25 ($12,242 vs. $3,673). Direct medical costs for MMVC 
were higher for Glargine ($668,027 vs. $754,435) Total medical costs were higher 
for glargine compared to LM25 ($971,663 vs. 1,141,628). ConClusions: Results 
of the present study suggest that compared with LM25, health care costs are 
significantly higher for glargine.
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objeCtives: To estimate the health economic impact of Sensor-Augmented 
Insulin Pump (SAP) Therapy among Insulin-Dependent Diabetes Mellitus (IDDM) 
patients in Colombia. Methods: The Core Diabetes Model (CDM) is highly vali-
dated, computer simulation model to determine the long-term health outcomes 
and economic consequences of diabetes interventions. A recent real life clinical 
study in Colombia evaluating 217 IDDM patients (average baseline HbA1c of 8.97%, 
mean age 34 years, and average diabetes duration of 14 years) who initiated SAP 
therapy showed that SAP therapy led to a reduction of -1.47% HbA1c as well as a 
significant reduction in severe hypoglycaemic events. The impact of the reduction 
in the fear of hypoglycaemic events on quality of life was also included. Results: 
Life expectancy of patients with SAP was increased by 3.51 years and diabetes 
related complications were delayed on average by 1.74 years. The Incremental-
Cost-Effectiveness-Ratio (ICER) for SAP was $44,889,916COP ($24,939USD) per 
Quality-Adjusted-Life-Year gained based on direct costs only. SAP related ther-
apy costs were partially offset by the savings due to the reduction in long-term 
complications, including proliferative diabetic retinopathy (PDR), Severe Vision 
Loss (SVL), End Stage Renal Disease (ESRD), and Amputations (AMP). The relative 
reduction in incidence of these complications (PDR 42%, SVL 20%, ESRD 46%, AMP 
12%) as well as the average delay in their onset (4.9 years, 4.0 years, 3.8 years, 3.7 
years, respectively) due to SAP therapy is profound. When including indirect costs, 
SAP demonstrated an even lower ICER. Extensive sensitivity analyses showed the 
robustness of the results. ConClusions: Using a payer’s perspective, our analysis 
showed that SAP is cost-effective over a lifetime horizon in IDDM patients in the 
Colombian setting (using a WTP threshold of $60,771,600COP [3x GDP]) and can 
lead to an increase in life expectancy. When using a societal perspective, SAP was 
even more cost-effective.
